Mer­ck­'s ADC hunt con­tin­ues with sec­ond deal for Chi­na biotech Kelun

Two months af­ter ink­ing a rel­a­tive­ly qui­et $47 mil­lion up­front deal with Chi­na’s Kelun Biotech, Mer­ck is back with an­oth­er deal, this time eye­ing an ADC for sol­id tu­mors.

The lat­est pact in­cludes $35 mil­lion up­front but is large­ly back­loaded with $901 mil­lion on the line, sim­i­lar to the first tie-up, which came in at $47 mil­lion to start and $1.3 bil­lion on the biobucks end.

As Mer­ck re­port­ed­ly cir­cles the wa­ters of Seagen, an ear­ly ADC leader and part­ner of the New Jer­sey Big Phar­ma, the com­pa­ny is deep­en­ing its pres­ence in the an­ti­body-drug con­ju­gate field to di­ver­si­fy its on­col­o­gy pipeline, ac­cord­ing to SVP of on­col­o­gy ear­ly de­vel­op­ment, Er­ic Ru­bin, in a state­ment Tues­day morn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.